Hope for duchenne: new drug shows promise in Long-Term trial

NCT ID NCT04428476

Ongoing Disease control Sponsor: Capricor Inc. Source: ClinicalTrials.gov ↗

First seen Nov 03, 2025 · Last updated May 16, 2026 · Updated 22 times

Summary

This study is for people with Duchenne muscular dystrophy who already completed the HOPE-2 trial. It tests the long-term safety and effectiveness of a drug called deramiocel, given as an IV infusion every three months for up to five years. The goal is to see if the drug can help maintain arm and hand function and is safe over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Children's Hospital Colorado

Aurora, Colorado, 80045, United States
Children's Hospital Wisconsin

Milwaukee, Wisconsin, 53226, United States
Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229, United States
University of California, Davis

Sacramento, California, 95817, United States
Washington University

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

DUCHENNE MUSCULAR DYSTROPHY